LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results^*

References

• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–781. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469–782. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469–78
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Heintjes EM, Kastelein JJ, et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006;15:435–433. Goettsch WG, Heintjes EM, Kastelein JJ, et al. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006;15:435–43
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025–334. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025–33
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1–105. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1–10
   PubMed Web of Science ®Google Scholar
• ATC/DDD system. World Health Organization. (Accessed at http://www.whocc.no/atcddd/.)6. ATC/DDD system. World Health Organization. (Accessed at http://www.whocc.no/atcddd/.)
   Google Scholar
• U.S. department of health and human services. (Accessed at http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/01_overview.asp.)7. U.S. department of health and human services. (Accessed at http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/01_overview.asp.)
   Google Scholar
• Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417–268. Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417–26
   PubMedGoogle Scholar
• Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–5039. Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434–503
   PubMed Web of Science ®Google Scholar
• Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91:3–10C, discussion C10. Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003;91:3–10C, discussion C
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–6011. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–60
   PubMed Web of Science ®Google Scholar
• Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007;64:276–8412. Bullano MF, Kamat S, Wertz DA, et al. Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 2007;64:276–84
   PubMed Web of Science ®Google Scholar
• Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383–9013. Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383–90
   PubMedGoogle Scholar
• Baessler A, Fischer M, Huf V, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol 2005;101:293–814. Baessler A, Fischer M, Huf V, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol 2005;101:293–8
   PubMed Web of Science ®Google Scholar
• Wei L, Macdonald TM, Watson AD, et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007;16:385–9215. Wei L, Macdonald TM, Watson AD, et al. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 2007;16:385–92
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154–916. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007;28:154–9
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389–9917. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389–99
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–6718. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• CBO/NHG. Multidisciplinaire richtlijn Cardiovasculair Risicomanagement. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO en Nederlands Huisartsen Genootschap 2006. Report No.: ISBN 10: 90-8523-131-0; ISBN 13: 978-90-8523-131-819. CBO/NHG. Multidisciplinaire richtlijn Cardiovasculair Risicomanagement. Utrecht: Kwaliteitsinstituut voor de gezondheidszorg CBO en Nederlands Huisartsen Genootschap 2006. Report No.: ISBN 10: 90-8523-131-0; ISBN 13: 978-90-8523-131-8
   Google Scholar